Comparative Pharmacology
Head-to-head clinical analysis: DISOPYRAMIDE PHOSPHATE versus NORPACE CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOPYRAMIDE PHOSPHATE versus NORPACE CR.
DISOPYRAMIDE PHOSPHATE vs NORPACE CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; inhibits cardiac sodium channels, prolongs action potential duration, increases effective refractory period, and reduces myocardial excitability and conduction velocity.
Class Ia antiarrhythmic agent; decreases myocardial excitability and conduction velocity, and prolongs refractory period by blocking sodium channels.
100-200 mg orally every 6 hours; immediate-release: 100-200 mg every 6 hours; extended-release: 200-300 mg every 12 hours.
Disopyramide controlled-release: 200 mg orally every 12 hours; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged to 15-25 hours in renal impairment (creatinine clearance <40 mL/min), requiring dose adjustment.
Terminal elimination half-life: 6-12 hours (normal renal function); prolonged to 12-20 hours in renal impairment. In coronary artery disease, half-life may be extended due to reduced clearance.
Renal excretion of unchanged drug accounts for 40-60% of elimination; hepatic metabolism (N-dealkylation) accounts for 20-30%; approximately 10-15% excreted in feces via biliary elimination.
Renal (50-57% unchanged), hepatic metabolism (30-40%), fecal (<10%). Dose adjustment required for CrCl <40 mL/min.
Category D/X
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)